All In Biotech

Drug Trial Radar · NCT06239727

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response: an Open Label, Non-Inferiority, Multicenter, Randomized Phase 3 Trial

Last checked: Nov 19, 2026Latest source record: Mar 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 593 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

593

Planned (sponsor's estimate)

Start

Mar 1, 2024

Primary completion

Feb 20, 2027

Study completion Feb 20, 2030

Sponsor

Lead sponsor
Sun Yat-sen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Jiangsu Hengrui Pharmaceutical Co., Ltd.
First posted
Feb 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an Open Label, Non-Inferiority, Multicenter, Randomized Phase 3 Trial aimed to investigate the impact of reduced-dose radiotherapy in combination with chemotherapy and immunotherapy on patients' prognosis and complication compared with conventional-dose radiotherapy in combination with chemotherapy and immunotherapy for treatment-sensitive stage III NPC patients screened out according to the treatment response.

Conditions

  • Nasopharyngeal Carcinoma

Interventions

  • PD-1 blocking antibodyDrug

    1. IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 200 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC. 2. Adjuvant PD-1 blocking antibody: every 3 weeks × 9 cycles; 200 mg, day 1.

  • GemcitabineDrug

    Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles.

  • Cisplatin (80 mg/m2)Drug

    Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles.

  • Reduced-dose Intensity-modulated radiotherapyRadiation

    1. Definitive IMRT, 30 fractions, 5 fractions/week, 1 fraction/day 2. Radiotherapy dose: pGTV: 6360cGy/30F; pCTV1: 5460cGy/30F; pCTV2: 4920cGy/30F.

  • Conventional-dose Intensity-modulated radiotherapyRadiation

    1. Definitive IMRT, 33 fractions, 5 fractions/week, 1 fraction/day 2. Radiotherapy dose: pGTV: 6996cGy/33F; pCTV1: 6006cGy/33F; pCTV2: 5412cGy/33F.

  • Cisplatin (100 mg/m2)Drug

    Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles

  • CapecitabineDrug

    Metronomic adjuvant capecitabine chemotherapy: 650 mg/m2 p.o. bid, 1 year, adminstration starts immediately after concurrent chemoradiotherapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Locoregional failure-free survival (LRFFS)Time frame: 3-year

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • Chongqing Cancer Hospital

    Chongqing, China · Recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China · Recruiting

  • Dongguan People's Hospital

    Dongguan, Guangdong, China · Recruiting

  • The First People's Hospital of Foshan

    Foshan, Guangdong, China · Recruiting

  • Sun Yat-Sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • The Affiliated Panyu Central Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China · Recruiting

  • Cancer Hospital of Shantou University Medical College

    Shantou, Guangdong, China · Recruiting

  • Affiliated Hospital of Guangdong Medical University

    Zhanjiang, Guangdong, China · Recruiting

  • Guangdong Nongken Central Hospital

    Zhanjiang, Guangdong, China · Recruiting

  • Cancer Hospital of Guangxi Medical University

    Nanning, Guangxi, China · Recruiting

  • Cancer Hospital of Guizhou Medical University

    Guiyang, Guizhou, China · Recruiting

  • The Second Affiliated Hospital of Hainan Medical University

    Haikou, Hainan, China · Recruiting

  • Hubei Province Cancer Hosiptal

    Wuhan, Hubei, China · Recruiting

  • Tongji Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • Xiangya Hospital Central South University

    Changsha, Hunan, China · Recruiting

  • Jiangsu Cancer Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Jiangsu Provinee Hospital of Chinese Medicine

    Nanjing, Jiangsu, China · Recruiting

  • Jiangxi Cancer Center

    Nanchang, Jiangxi, China · Recruiting

  • The First Affiliated Hospital of Xian Jiaotong University

    Xian, Shanxi, China · Recruiting

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, China · Recruiting

  • West China Hospital,Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.